Inhaled Corticosteroids - Pharmacology

SECTION 1

Historical Context & Motivation

Before the development of inhaled corticosteroids (ICS), the management of chronic airway diseases such as asthma relied heavily on systemic corticosteroids administered orally or parenterally. While these agents were effective in suppressing the underlying inflammatory cascade, their prolonged use was accompanied by debilitating adverse effects including adrenal suppression, osteoporosis, hyperglycemia, and Cushing syndrome. The recognition that airway inflammation — rather than bronchospasm alone — was the central pathophysiological feature of asthma created an urgent need for a therapeutic strategy that could deliver potent anti-inflammatory action directly to the lungs while minimizing systemic exposure.

The quest to localize corticosteroid therapy to the respiratory tract drove decades of pharmaceutical innovation, ultimately yielding agents with high topical potency, rapid hepatic first-pass metabolism, and formulations optimized for pulmonary deposition. The timeline below traces the critical milestones that shaped the modern ICS landscape.

1950s • Systemic Corticosteroids for Asthma

Oral cortisone and prednisone were introduced for severe asthma, demonstrating dramatic efficacy but also revealing the serious consequences of chronic systemic glucocorticoid exposure, including adrenal axis suppression and metabolic derangements.

1972 • Beclomethasone Dipropionate Approved

Beclomethasone dipropionate became the first ICS approved for asthma management. Delivered via metered-dose inhaler, it demonstrated that topical corticosteroid therapy could control airway inflammation with significantly fewer systemic side effects than oral alternatives.

1987 • Budesonide Enters the Market

Budesonide was introduced with improved pharmacokinetic properties, including high first-pass hepatic metabolism (~90%), which further reduced systemic bioavailability and enhanced the therapeutic index of ICS therapy.

1994 • Fluticasone Propionate Launched

Fluticasone propionate offered markedly higher glucocorticoid receptor binding affinity relative to earlier agents, allowing lower doses to achieve equivalent anti-inflammatory effects and establishing a new benchmark for ICS potency.

2000s–Present • Combination Inhalers & Novel Agents

Fixed-dose combination inhalers pairing ICS with long-acting β₂-agonists (LABA) — such as fluticasone/salmeterol and budesonide/formoterol — became standard of care. Newer molecules like fluticasone furoate offered once-daily dosing and ultra-high receptor affinity.

The evolution from systemic to inhaled corticosteroid therapy represents one of the most significant advances in respiratory medicine. The central question this development answered was: How can we harness the potent anti-inflammatory properties of glucocorticoids while confining their action to the target organ and minimizing the systemic toxicity that limits chronic use? Understanding the pharmacology of ICS is fundamental to optimizing therapy for millions of patients with obstructive airway diseases.

SECTION 2

Core Principles & Definitions

Inhaled corticosteroids exert their therapeutic effects through a well-characterized genomic mechanism that ultimately suppresses the expression of pro-inflammatory mediators in the airway. To appreciate their clinical utility, one must understand several foundational principles governing their pharmacology, including receptor-mediated gene regulation, the concept of topical potency, the importance of pulmonary deposition, and the pharmacokinetic features that determine systemic exposure.

Glucocorticoid Receptor Activation

ICS molecules diffuse across airway epithelial cell membranes and bind to the intracellular glucocorticoid receptor (GR). The activated GR–ligand complex translocates to the nucleus and modulates gene transcription, upregulating anti-inflammatory proteins (transactivation) and suppressing pro-inflammatory cytokines (transrepression).

Topical Potency vs. Systemic Bioavailability

An ideal ICS exhibits high topical potency — measured by receptor binding affinity — while maintaining low systemic bioavailability. Extensive first-pass hepatic metabolism of the swallowed fraction is a key pharmacokinetic property that distinguishes safer ICS agents from their predecessors.

Pulmonary Deposition Fraction

Only a fraction of the inhaled dose — typically 10–40% depending on the device and technique — actually reaches the lower airways. The remainder deposits in the oropharynx and is swallowed, underscoring why patient inhalation technique and device selection are critical determinants of efficacy.

Anti-Inflammatory Cascade Suppression

ICS reduce the recruitment and activation of eosinophils, mast cells, T-lymphocytes, macrophages, and dendritic cells in the airway. They also decrease vascular permeability, mucus hypersecretion, and airway hyperresponsiveness by suppressing mediators such as IL-4, IL-5, IL-13, and TNF-α.

Onset and Duration of Action

Because ICS work primarily through genomic mechanisms (altering gene transcription), their clinical effects develop over days to weeks rather than within minutes. They are therefore classified as controller medications, not rescue agents, and must be used consistently for optimal benefit.

✦

KEY TAKEAWAY

Think of inhaled corticosteroids like a precision sprinkler system in a building rather than flooding the entire structure with water. Systemic corticosteroids 'flood' every organ with drug, causing widespread collateral effects. ICS deliver the anti-inflammatory agent directly to the 'fire' — the inflamed airway — while engineered pharmacokinetic features ensure that any drug escaping into the systemic circulation is rapidly inactivated by hepatic metabolism, much like drainage channels divert excess water before it causes structural damage elsewhere.

SECTION 3

Mechanism of Action — Visual Explanation

This diagram traces the journey of an ICS molecule from the inhaler to the airway epithelial cell nucleus. After depositing on the airway surface and diffusing across the cell membrane, the drug binds the intracellular glucocorticoid receptor (GR). The activated ICS–GR complex translocates into the nucleus and binds glucocorticoid response elements (GRE) on DNA. Two complementary genomic effects follow: transactivation (upregulation of anti-inflammatory proteins) and transrepression (suppression of pro-inflammatory cytokines and enzymes).

The diagram above illustrates the predominant mechanism by which ICS exert their anti-inflammatory effects. It is important to note that the clinical benefits of this genomic pathway require hours to days to manifest, which is why ICS are unsuitable as rescue medications. Transrepression — specifically the inhibition of NF-κB and AP-1 transcription factors — is considered the primary mechanism responsible for the anti-inflammatory efficacy of ICS, while transactivation of metabolic genes is implicated in many of the adverse effects (e.g., gluconeogenesis, protein catabolism). Newer ICS research has therefore focused on developing 'dissociated' glucocorticoids that preferentially activate transrepression pathways.

SECTION 4

Pharmacokinetics & Drug Disposition

The pharmacokinetic profile of an ICS is a critical determinant of both its efficacy and its safety. After inhalation, the administered dose is partitioned between the lungs (the therapeutic target) and the oropharynx (the source of local adverse effects and, after swallowing, potential systemic exposure). Understanding the key pharmacokinetic parameters — pulmonary deposition, oral bioavailability, volume of distribution, protein binding, and clearance — allows clinicians to make informed choices among available agents and to counsel patients effectively on proper inhaler technique.

Key Pharmacokinetic Relationships

SYSTEMIC BIOAVAILABILITY

F_systemic = F_lung + F_oral × (1 − F_first-pass)

Where F_systemic = total systemic bioavailability; F_lung = fraction deposited in the lung (enters systemic circulation directly, bypassing first-pass metabolism); F_oral = fraction deposited in the oropharynx and swallowed; F_first-pass = fraction of swallowed drug inactivated by hepatic first-pass metabolism. A high F_first-pass minimizes the systemic contribution of the swallowed fraction.

THERAPEUTIC INDEX CONCEPT

TI ∝ (Topical potency × F_lung) / F_systemic

The therapeutic index (TI) of an ICS is proportional to the ratio of its local anti-inflammatory effect (driven by topical potency and lung deposition) to its systemic exposure. Agents like fluticasone propionate achieve a favorable TI through very high receptor affinity combined with extensive first-pass metabolism (>99% oral first-pass inactivation).

The clinical implication of these relationships is profound. For an agent like budesonide, approximately 90% of the swallowed dose undergoes first-pass hepatic metabolism via CYP3A4, meaning that the swallowed fraction contributes negligibly to systemic drug levels. The lung-deposited fraction therefore becomes the dominant determinant of both therapeutic effect and systemic exposure. This pharmacokinetic reality explains why optimizing inhaler technique and selecting an appropriate delivery device are not mere ancillary considerations — they are pharmacokinetically central to clinical outcomes.

💡

Clinical Pearl

Mouth rinsing after ICS administration reduces oropharyngeal deposition of drug, thereby decreasing the risk of oropharyngeal candidiasis and dysphonia. For agents with low first-pass metabolism (e.g., beclomethasone dipropionate), rinsing also meaningfully reduces systemic absorption of the swallowed fraction.

SECTION 5

Classification & Comparative Pharmacology

Several ICS agents are available for clinical use, and while they share a common mechanism of action, they differ substantially in their pharmacokinetic and pharmacodynamic profiles. Clinically relevant differences include receptor binding affinity (a proxy for topical potency), lipophilicity (which influences pulmonary retention and dissolution rate), oral bioavailability, and half-life. The table below provides a comparative overview of the most commonly prescribed ICS agents, and the subsequent diagram visually maps their relative potency.

ICS Agent	Relative Potency (Dexamethasone = 1)	Oral Bioavailability (%)	Lipophilicity	Half-Life (h)
Beclomethasone DP	≈ 600	≈ 20–25	Moderate	≈ 2.8
Budesonide	≈ 980	≈ 6–11	Moderate	≈ 2.0–3.6
Fluticasone Propionate	≈ 1800	< 1	High	≈ 7.8
Fluticasone Furoate	≈ 2900	< 1	Very High	≈ 14–17
Ciclesonide (active metabolite)	≈ 1200	< 1	High	≈ 3.4–5.1
Mometasone Furoate	≈ 2200	< 1	High	≈ 4.5–5.8

Comparative pharmacokinetic and pharmacodynamic properties of commonly prescribed inhaled corticosteroids.

Horizontal bar chart comparing the relative glucocorticoid receptor binding affinity of six ICS agents. Fluticasone furoate has the highest affinity (≈2900), while beclomethasone dipropionate has the lowest among this group (≈600). Higher binding affinity generally correlates with greater topical potency, but clinical outcomes also depend on pharmacokinetic factors such as lung deposition and systemic clearance.

Several features distinguish the newer-generation ICS agents from earlier compounds. Ciclesonide is a notable prodrug — it is inactive until converted to its active metabolite (desisobutyryl-ciclesonide) by esterases in the lung, thereby minimizing oropharyngeal adverse effects. Fluticasone furoate possesses the longest half-life and highest receptor binding affinity in the class, enabling effective once-daily dosing. Higher lipophilicity generally translates to longer pulmonary retention time because the drug partitions more avidly into the lipid bilayer of airway cells, creating a local depot effect that sustains the anti-inflammatory action between doses.

SECTION 6

Worked Example: ICS Drug Selection & Dose Adjustment

The following clinical scenario demonstrates how pharmacokinetic and pharmacodynamic principles are applied when selecting and adjusting ICS therapy in practice. This example integrates concepts of relative potency, dose equivalency, and patient-specific factors.

Switching ICS Agents: Beclomethasone to Fluticasone Propionate

1
Step 1 — Clinical Scenario

A 34-year-old patient with moderate persistent asthma is currently controlled on beclomethasone dipropionate 200 µg BID via MDI (total daily dose: 400 µg/day). The clinician wishes to switch to fluticasone propionate due to its lower oral bioavailability and higher therapeutic index. What is the equipotent dose of fluticasone propionate?
2
Step 2 — Identify Dose Equivalency Ratio

According to GINA (Global Initiative for Asthma) dose equivalency tables and clinical guidelines, fluticasone propionate is approximately twice as potent as beclomethasone dipropionate on a microgram-for-microgram basis. The approximate equivalency ratio is: 200 µg beclomethasone ≈ 100 µg fluticasone propionate.

Equivalency ratio: BDP : FP ≈ 2 : 1
3
Step 3 — Calculate Equipotent Dose

Current total daily dose of beclomethasone = 400 µg/day. Applying the 2:1 ratio: Equipotent fluticasone propionate dose = 400 µg ÷ 2 = 200 µg/day. This can be administered as 100 µg BID or, depending on the formulation, 200 µg once daily if using a once-daily approved product.

Equipotent daily dose of fluticasone propionate: 200 µg/day
4
Step 4 — Verify GINA Classification Step

Consulting the GINA dose classification for adults: fluticasone propionate 100–250 µg/day is classified as a low dose; 250–500 µg/day as medium dose; >500 µg/day as high dose. The calculated equipotent dose of 200 µg/day falls within the low-dose range, consistent with the patient's classification of moderate persistent asthma currently controlled at the equivalent low-dose beclomethasone level.

GINA classification: Low-dose ICS
5
Step 5 — Patient Counseling Considerations

Advise the patient that both medications work through the same mechanism and the switch should maintain equivalent asthma control. Reinforce the importance of proper MDI technique (slow, deep inhalation, 10-second breath hold) and mouth rinsing after each use. Given fluticasone propionate's negligible oral bioavailability (<1%), mouth rinsing in this case primarily prevents oropharyngeal candidiasis rather than reducing systemic exposure.

SECTION 7

Adverse Effects & Clinical Limitations

While inhaled corticosteroids have dramatically improved the safety profile of chronic corticosteroid therapy, they are not without adverse effects. These effects are broadly categorized into local (oropharyngeal) effects related to drug deposition in the upper airway, and systemic effects that emerge with high doses or prolonged use. The clinical significance of these adverse effects varies among agents, largely reflecting differences in pharmacokinetic properties discussed in earlier sections.

Category	Adverse Effect	Mechanism / Risk Factors
Local	Oropharyngeal candidiasis (thrush)	Local immunosuppression of mucosal defenses; higher with poor technique and high doses. Mitigated by spacer use and mouth rinsing.
Local	Dysphonia (hoarseness)	Corticosteroid-induced myopathy of laryngeal muscles; affects up to 5–10% of users. Reversible upon dose reduction or drug holiday.
Local	Reflex cough / throat irritation	Propellant or powder particle deposition triggering upper airway reflexes; may improve with spacer use or switching formulation.
Systemic	HPA axis suppression	Dose-dependent suppression of the hypothalamic-pituitary-adrenal axis; clinically significant primarily at high doses (>1000 µg/day BDP equivalent) or with concurrent systemic steroid use.
Systemic	Reduced bone mineral density	Inhibition of osteoblast function and intestinal calcium absorption; risk increases with dose and duration. Low-to-medium doses generally do not significantly affect BMD.
Systemic	Growth suppression in children	Modest reduction in growth velocity (≈0.5–1.5 cm in first year); effect appears to diminish over time and final adult height may not be significantly affected at low-to-medium doses.
Systemic	Posterior subcapsular cataracts / glaucoma	Rare; risk is dose- and duration-dependent. More commonly associated with concurrent systemic or ophthalmic corticosteroid use.

Local and systemic adverse effects of inhaled corticosteroids with their mechanisms and risk factors.

⚖️

CLINICAL BALANCE

The risk–benefit calculus for ICS in asthma overwhelmingly favors their use. The systemic adverse effects of ICS at recommended doses are minor compared to the morbidity and mortality associated with uncontrolled asthma — including airway remodeling, frequent exacerbations, and the inevitable recourse to oral corticosteroids with their far greater systemic toxicity. Think of the ICS safety profile like wearing a seatbelt: there is a small theoretical risk of harm in edge cases, but the protection provided in the vast majority of scenarios makes it unreasonable not to use the intervention.

SECTION 8

ICS in the Broader Therapeutic Landscape

Inhaled corticosteroids are rarely used in isolation in modern respiratory medicine. The stepwise approach to asthma and COPD management integrates ICS with other pharmacological classes, and understanding these therapeutic partnerships is essential. Furthermore, the limitations of ICS — particularly in steroid-resistant phenotypes and non-eosinophilic inflammation — have driven the development of biologic agents that target specific molecular pathways in severe disease.

Feature	ICS Monotherapy	ICS + LABA Combination	Biologic Agents (anti-IgE, anti-IL-5)
Mechanism	Genomic anti-inflammatory (transrepression / transactivation)	Anti-inflammatory + sustained bronchodilation via β₂-receptor agonism and synergistic GR nuclear translocation	Targeted blockade of specific immunoglobulin or cytokine pathways (e.g., omalizumab blocks IgE; mepolizumab blocks IL-5)
Indication	Mild persistent asthma (GINA Step 2)	Moderate-to-severe persistent asthma (GINA Steps 3–4); COPD with frequent exacerbations	Severe refractory asthma with specific biomarker phenotypes (elevated IgE, eosinophilia)
Administration	Inhaled (MDI, DPI, nebulizer)	Inhaled fixed-dose combination (single inhaler)	Subcutaneous injection or intravenous infusion
Key Limitation	May be insufficient for moderate-to-severe disease; does not address bronchospasm	LABA should never be used without ICS (risk of asthma-related mortality as monotherapy); systemic effects at high ICS doses	High cost; restricted to specialist-initiated therapy; does not replace ICS for most patients
Examples	Fluticasone propionate, budesonide, beclomethasone	Fluticasone/salmeterol (Advair), budesonide/formoterol (Symbicort)	Omalizumab (Xolair), mepolizumab (Nucala), dupilumab (Dupixent)

Comparison of ICS monotherapy, ICS-LABA combination therapy, and biologic agents in asthma management.

An important emerging concept is the anti-inflammatory reliever (AIR) strategy, endorsed in recent GINA guidelines, which uses budesonide/formoterol as both a maintenance and as-needed reliever therapy. This approach ensures that patients receive anti-inflammatory treatment with every puff — even during rescue use — thereby reducing the dissociation between symptom relief (bronchodilation) and disease control (inflammation suppression) that historically plagued SABA-only rescue regimens. Looking forward, the development of selective glucocorticoid receptor modulators (SGRMs) and dissociated glucocorticoids — agents that preferentially activate transrepression over transactivation — holds promise for retaining anti-inflammatory efficacy while further reducing metabolic side effects.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why inhaled corticosteroids are classified as controller medications rather than rescue medications. In your answer, describe the primary mechanism of action (genomic vs. non-genomic) and how this relates to their onset of action.

Show answer

Inhaled corticosteroids are controller medications because their anti-inflammatory effects are mediated primarily through a genomic mechanism — binding the intracellular glucocorticoid receptor, translocating to the nucleus, and modulating gene transcription. This process requires hours to days to produce measurable changes in inflammatory mediator levels and days to weeks to achieve full clinical benefit. Unlike rescue bronchodilators (e.g., short-acting β₂-agonists), which produce smooth muscle relaxation within minutes via direct receptor activation on airway smooth muscle cells, ICS do not provide immediate symptom relief during an acute asthma exacerbation. Their value lies in reducing the underlying airway inflammation, thereby preventing exacerbations and improving long-term disease control when used consistently.

Question 2: BASIC CALCULATION

A patient is being switched from budesonide 400 µg BID (total daily dose = 800 µg/day) to fluticasone propionate. Using the approximate dose equivalency ratio of budesonide : fluticasone propionate ≈ 2 : 1, calculate the equipotent total daily dose of fluticasone propionate. Classify this dose according to GINA guidelines (low: 100–250 µg/day; medium: >250–500 µg/day; high: >500 µg/day for fluticasone propionate in adults).

Show answer

Applying the 2:1 equivalency ratio: 800 µg budesonide ÷ 2 = 400 µg/day fluticasone propionate. According to GINA dose classifications, fluticasone propionate at 400 µg/day falls within the medium-dose range (>250–500 µg/day). This could be administered as 200 µg BID via MDI or DPI. This classification is clinically important because it determines the GINA treatment step and guides decisions about step-up or step-down therapy.

Question 3: INTERMEDIATE

A patient using a standard pMDI (pressurized metered-dose inhaler) without a spacer achieves approximately 10–15% pulmonary deposition, with 60–70% depositing in the oropharynx and being swallowed. Compare the expected systemic bioavailability of the swallowed fraction for beclomethasone dipropionate (oral bioavailability ≈ 20%) versus fluticasone propionate (oral bioavailability < 1%). How does this difference influence the clinical significance of poor inhaler technique for each agent?

Show answer

With poor technique and no spacer, a large fraction (60–70%) of the dose deposits in the oropharynx and is swallowed. For beclomethasone dipropionate, approximately 20% of this swallowed fraction survives first-pass metabolism and enters the systemic circulation, contributing significantly to F_systemic. If 65% of a 200 µg dose is swallowed (130 µg), about 26 µg would reach the systemic circulation from the oral route alone. For fluticasone propionate, with <1% oral bioavailability, essentially none of the swallowed 130 µg enters the systemic circulation (<1.3 µg). This means poor inhaler technique with beclomethasone carries a meaningfully higher risk of systemic adverse effects (HPA suppression, etc.) compared to fluticasone propionate. Conversely, both agents lose therapeutic efficacy with poor technique because less drug reaches the lungs — the critical distinction is that beclomethasone 'pays twice' with both reduced efficacy and increased systemic risk.

Question 4: APPLIED

A 7-year-old child with moderate persistent asthma has been on medium-dose ICS for 18 months. The parents express concern because their pediatrician mentioned a possible effect on growth. The child's growth velocity has decreased from the 50th percentile to the 35th percentile over the past year. As a clinical pharmacist, how would you address the parents' concerns? Discuss the evidence regarding ICS and growth in children, the clinical significance of the observed growth velocity change, and any strategies to mitigate this effect while maintaining asthma control.

Show answer

The parents' concern is valid and well-documented. Studies, including the CAMP trial, have shown that ICS can reduce growth velocity by approximately 0.5–1.5 cm in the first 1–2 years of therapy, primarily affecting prepubertal children. However, several important points should be communicated. First, this growth suppression is dose-dependent — the lowest effective dose should always be used. Second, the effect tends to attenuate after the first year and studies suggest the impact on final adult height is modest (≈0.5–1.2 cm average reduction). Third, uncontrolled asthma itself impairs growth due to chronic inflammation, frequent exacerbations, and the potential need for oral corticosteroid bursts, which have far greater growth-suppressive effects. Mitigation strategies include stepping down to the lowest effective ICS dose, using an agent with high first-pass metabolism (budesonide, fluticasone), using a spacer device to optimize lung deposition and reduce systemic absorption, and monitoring growth velocity at regular intervals. The goal is to use the minimum dose needed to maintain asthma control while monitoring for any clinically meaningful growth trajectory changes.

Question 5: CRITICAL THINKING

Ciclesonide is a prodrug that requires activation by pulmonary esterases to form its active metabolite, des-ciclesonide. Additionally, approximately 99% of des-ciclesonide is protein-bound in the systemic circulation. Critically analyze how these two pharmacokinetic features — prodrug activation and high protein binding — contribute to ciclesonide's favorable safety profile. Then evaluate whether these features alone make ciclesonide superior to fluticasone propionate, considering receptor binding affinity, clinical trial data, and any potential limitations of the prodrug approach.

Show answer

Ciclesonide's prodrug design provides a significant advantage: the parent compound is pharmacologically inactive, so drug depositing in the oropharynx does not exert local immunosuppressive effects, theoretically reducing the incidence of candidiasis and dysphonia. The active metabolite (des-ciclesonide) is generated selectively in the lungs by esterases, creating a tissue-targeted activation profile. Furthermore, the 99% protein binding of des-ciclesonide means that only ~1% circulates as free, pharmacologically active drug systemically, further limiting systemic adverse effects. However, 'superiority' over fluticasone propionate is not straightforward. Fluticasone propionate has substantially higher GR binding affinity (≈1800 vs. ≈1200 for des-ciclesonide), which may allow lower nominal doses for equivalent efficacy. Clinical trial data comparing the two agents directly are limited, and head-to-head studies have generally shown comparable efficacy at equipotent doses. A potential limitation of the prodrug approach is that activation depends on pulmonary esterase activity, which could theoretically vary among patients or be affected by disease states. Additionally, in severe disease with significant airway remodeling and mucus plugging, drug deposition patterns may shift, potentially reducing esterase-mediated activation. Therefore, while ciclesonide's pharmacokinetic profile offers theoretical safety advantages — particularly regarding local adverse effects — clinical superiority over well-established agents like fluticasone propionate requires evaluation of the totality of evidence, including efficacy outcomes, patient adherence, cost, and available combination formulations.

SUMMARY

Inhaled Corticosteroids — Summary Review

Summary

Inhaled corticosteroids are the cornerstone controller medications for persistent asthma and play an important role in COPD management. They act by binding the intracellular glucocorticoid receptor (GR), with the activated GR–ligand complex translocating to the nucleus to modulate gene expression through transactivation (upregulation of anti-inflammatory proteins) and transrepression (suppression of pro-inflammatory cytokines via NF-κB and AP-1 inhibition). Because this genomic mechanism requires time for altered protein synthesis, the onset of clinical benefit is measured in days to weeks, and ICS must be used consistently as maintenance therapy rather than for acute relief.

Key pharmacokinetic features that determine the safety profile include pulmonary deposition fraction (influenced by device type and inhalation technique), oral bioavailability (minimized by extensive hepatic first-pass metabolism), and receptor binding affinity (which dictates topical potency). Agents range from beclomethasone dipropionate — the first approved ICS — to newer molecules like fluticasone furoate and ciclesonide (a prodrug activated by pulmonary esterases). Local adverse effects include oropharyngeal candidiasis and dysphonia (mitigated by spacer use and mouth rinsing), while systemic effects such as HPA axis suppression and reduced bone mineral density are generally dose-dependent and clinically significant primarily at high doses. In modern practice, ICS are frequently combined with long-acting β₂-agonists (LABA) in fixed-dose combination inhalers, and biologic agents offer additional targeted therapy for patients with severe refractory disease.